The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level

Stephen D. Turley, John M. Dietschy

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Elevated plasma low-density lipoprotein cholesterol levels constitute a major risk factor for coronary heart disease. The plasma low-density lipoprotein cholesterol concentration is dictated partly by the efficiency of intestinal cholesterol absorption. The efficacy of treatments designed to block cholesterol absorption is partially offset to the extent that the liver compensates for the interruption to the enterohepatic movement of cholesterol by increasing the rate at which it synthesizes cholesterol. Currently, the most widely-used treatment for hypercholesterolemia is based on a class of agents (statins) that partially inhibit cholesterol synthesis within the body. Recent clinical trials with a unique, potent, and selective cholesterol absorption inhibitor (ezetimibe) used in combination with lower doses of various statins showed an additive reduction in plasma low-density lipoprotein cholesterol levels which equaled the reduction achieved with maximal doses of statins given alone. Combination therapy using a statin and this novel cholesterol absorption inhibitor represents an efficacious new approach to the treatment of hypercholesterolemia in the general population.

Original languageEnglish (US)
Pages (from-to)29-33+64
JournalPreventive Cardiology
Volume6
Issue number1
StatePublished - Dec 2003

Fingerprint

Dietary Cholesterol
Intestinal Absorption
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol
LDL Cholesterol
Anticholesteremic Agents
Pharmaceutical Preparations
Hypercholesterolemia
Coronary Disease
Clinical Trials
Liver
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Public Health, Environmental and Occupational Health

Cite this

The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level. / Turley, Stephen D.; Dietschy, John M.

In: Preventive Cardiology, Vol. 6, No. 1, 12.2003, p. 29-33+64.

Research output: Contribution to journalArticle

@article{a91d5ab2ea214234b46d5595c94b378f,
title = "The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level",
abstract = "Elevated plasma low-density lipoprotein cholesterol levels constitute a major risk factor for coronary heart disease. The plasma low-density lipoprotein cholesterol concentration is dictated partly by the efficiency of intestinal cholesterol absorption. The efficacy of treatments designed to block cholesterol absorption is partially offset to the extent that the liver compensates for the interruption to the enterohepatic movement of cholesterol by increasing the rate at which it synthesizes cholesterol. Currently, the most widely-used treatment for hypercholesterolemia is based on a class of agents (statins) that partially inhibit cholesterol synthesis within the body. Recent clinical trials with a unique, potent, and selective cholesterol absorption inhibitor (ezetimibe) used in combination with lower doses of various statins showed an additive reduction in plasma low-density lipoprotein cholesterol levels which equaled the reduction achieved with maximal doses of statins given alone. Combination therapy using a statin and this novel cholesterol absorption inhibitor represents an efficacious new approach to the treatment of hypercholesterolemia in the general population.",
author = "Turley, {Stephen D.} and Dietschy, {John M.}",
year = "2003",
month = "12",
language = "English (US)",
volume = "6",
pages = "29--33+64",
journal = "Preventive Cardiology",
issn = "1520-037X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level

AU - Turley, Stephen D.

AU - Dietschy, John M.

PY - 2003/12

Y1 - 2003/12

N2 - Elevated plasma low-density lipoprotein cholesterol levels constitute a major risk factor for coronary heart disease. The plasma low-density lipoprotein cholesterol concentration is dictated partly by the efficiency of intestinal cholesterol absorption. The efficacy of treatments designed to block cholesterol absorption is partially offset to the extent that the liver compensates for the interruption to the enterohepatic movement of cholesterol by increasing the rate at which it synthesizes cholesterol. Currently, the most widely-used treatment for hypercholesterolemia is based on a class of agents (statins) that partially inhibit cholesterol synthesis within the body. Recent clinical trials with a unique, potent, and selective cholesterol absorption inhibitor (ezetimibe) used in combination with lower doses of various statins showed an additive reduction in plasma low-density lipoprotein cholesterol levels which equaled the reduction achieved with maximal doses of statins given alone. Combination therapy using a statin and this novel cholesterol absorption inhibitor represents an efficacious new approach to the treatment of hypercholesterolemia in the general population.

AB - Elevated plasma low-density lipoprotein cholesterol levels constitute a major risk factor for coronary heart disease. The plasma low-density lipoprotein cholesterol concentration is dictated partly by the efficiency of intestinal cholesterol absorption. The efficacy of treatments designed to block cholesterol absorption is partially offset to the extent that the liver compensates for the interruption to the enterohepatic movement of cholesterol by increasing the rate at which it synthesizes cholesterol. Currently, the most widely-used treatment for hypercholesterolemia is based on a class of agents (statins) that partially inhibit cholesterol synthesis within the body. Recent clinical trials with a unique, potent, and selective cholesterol absorption inhibitor (ezetimibe) used in combination with lower doses of various statins showed an additive reduction in plasma low-density lipoprotein cholesterol levels which equaled the reduction achieved with maximal doses of statins given alone. Combination therapy using a statin and this novel cholesterol absorption inhibitor represents an efficacious new approach to the treatment of hypercholesterolemia in the general population.

UR - http://www.scopus.com/inward/record.url?scp=0037413223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037413223&partnerID=8YFLogxK

M3 - Article

C2 - 12624559

AN - SCOPUS:0037413223

VL - 6

SP - 29-33+64

JO - Preventive Cardiology

JF - Preventive Cardiology

SN - 1520-037X

IS - 1

ER -